Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy.

To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients. 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 anti-Spike protein IgG and neutralizing antibody 2 months following vaccination were measured by ELIZA. Injection site pain and fever were the most common local and systemic side effects. The overall seroconversion rate was 86.9% that was lower in older age, those with hematological malignancies and chemotherapy receivers. The result of study confirmed the safety and short-term efficacy of inactivated vaccine in patients with malignancies. [ABSTRACT FROM AUTHOR]